Abstract: Fabry disease is a rare lysosomal storage disorder, inherited in an X-linked manner. It is characterized by the deficiency of the enzyme alpha-galactosidase, leading to a buildup of glycosphingolipids in the cells. Angiokeratoma is one of the cutaneous manifestations of this condition, and it helps making the diagnosis. The typical site involves the genital area in men and lumbosacral, buttocks and trunk region in both sexes. We report a case of genital angiokeratoma in a woman with Fabry disease. The diagnosis is through molecular analysis and, when made early, starting treatment reduces the morbidity and mortality of the disease. Thus, the dermatologist has an important role in the identification of angiokeratoma as a cutaneous marker, and the knowledge of its different presentations is essential for the early diagnosis and management of Fabry disease.
INTRODUCTION
Fabry disease (FD) is a rare storage disorder, first described in 1898 as angiokeratoma corporis diffusum by Anderson and Fabry.
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Subsequently, it was described as a systemic metabolic disease, affecting cells of the vascular endothelium, smooth muscle, myocardium, renal epithelium and central nervous system. The time between the onset of symptoms and the diagnosis can be longer than 10 years. 3 FD is a lysosomal disease, inherited in an X-linked manner. 4 The affected gene is called GLA and leads to the deficiency of the enzyme alpha galactosidase, with subsequent buildup of glycosphingolipids in the vascular endothelium, smooth muscle, myocardium, renal epithelium and central nervous system. In male patients, the gene has a high penetrance, originating the so called classic phenotype of the disease. 5 The diagnosis in this population is through the dosage of the enzymatic activity of alpha galactosidase. 6 In female patients, the disease has variable expression due to the random inactivation of one of the X chromosomes, according to the hypothesis of Lyon. 7 Currently, heterozygous patients are not considered only carriers, since they present systemic changes related to the disease and increased mortality. In women, the diagnosis is through molecular analysis of the GLA gene, since the dosage of the enzyme can be abnormal, as in men, or normal, as in healthy individuals. reduce morbidity and mortality in these patients.
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CASE REPORT
Female, 52-year-old patient with FD, diagnosed two years prior to the consultation through family screening. She was the first daughter of a non-blood-related relationship, and her brother was the index case of the family. He had had renal transplantation and Subsequently, they can appear on the lips, navel, nails and palms.
Men have a larger number of lesions. Women rarely present AKs on the trunk and genital regions. 2 In a Medline and Embase database review, we did not find any similar cases in the literature till present.
Among the dermatologic lesions we can find -besides AKs -telangiectasias, lymphedema and anhidrosis. The patient had angiomas. The son had hypohidrosis, and the brother had fixed lymphedema of the lower limbs.
The dermoscopy is helpful in detecting multiple AKs that are not always seen on clinical examination alone. In this case, they had a multilobular vascular configuration, described as a well-defined red lake, with white-yellow areas corresponding to hyperkeratosis. 3 According to the description in the literature, some ERT is available since 2001 for FD and is the only therapeutic option till present. [7] [8] [9] In Brazil, it is indicated to patients older Our patient is under treatment with ERT for 12 months and improved from the acroparesthesia. For the time being, the AK is being monitored clinically.
Genital angiokeratoma in a woman with Fabry disease: the dermatologist's role
In conclusion, we can say that AK is an important cutaneous marker in screening patients for FD, and the knowledge of this lesions is helpful in identifying the disease early. 
